Sign up to save your podcasts
Or
Share The Lancet Oncology: January 25, 2013
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Lancet Oncology: January 25, 2013
John Farley discusses a trial of the MEK inhibitor selumetinib for the treatement of low-grade serous carcinoma of the ovary and peritoneum.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
View all episodes
By The Lancet Group
5
11 ratings
John Farley discusses a trial of the MEK inhibitor selumetinib for the treatement of low-grade serous carcinoma of the ovary and peritoneum.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More shows like The Lancet Oncology in conversation with
View all
JAMA Editors' Summary
135 Listeners
Annals of Internal Medicine Podcast
136 Listeners
NEJM This Week
325 Listeners
JAMA Clinical Reviews
504 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Medicine and Science from The BMJ
37 Listeners
Nature Podcast
758 Listeners
THE ADAM BUXTON PODCAST
1,045 Listeners
Science Magazine Podcast
817 Listeners
The Peter Attia Drive
8,041 Listeners
Blood Podcast
53 Listeners
The Lancet Voice
22 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
The Lancet Global Health in conversation with
2 Listeners
The Lancet Psychiatry in conversation with
0 Listeners
The Lancet Respiratory Medicine in conversation with
1 Listeners
The Lancet in conversation with
0 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
0 Listeners
The Lancet Diabetes & Endocrinology in conversation with
1 Listeners
The Lancet Infectious Diseases in conversation with
0 Listeners
The Lancet Public Health in conversation with
1 Listeners
The Lancet Microbe in conversation with
0 Listeners
eBioMedicine in conversation with
0 Listeners
In conversation with...
0 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
The Lancet Regional Health in conversation with
0 Listeners
The Lancet Primary Care in conversation with
0 Listeners
The Lancet Regional Health Americas in conversation with
0 Listeners